Celularity Inc.
CELUW
NASDAQ Capital Market0.01
USD
+0.00
- -
CIK
0001752828
ISIN
US1511901134
CUSIP
151190113
Return %
Stock
S&P500
1Y
-88.00
26.53
3Y
-90.48
76.60
5Y
-99.51
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Robert Joseph Hariri
- Full Time Employees
- 120
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 170 Park Avenue Florham Park NJ United States of America 07932
- IPO Date
- Jul 19, 2021
- CIK
- 0001752828
- Website
- celularity.com
- Similar Companies
- Business
- Celularity Inc. (NASDAQ: CELU) is a clinical-stage biotechnology company that develops and commercializes off-the-shelf allogeneic placental-derived cell therapies and advanced biomaterial products targeting aging-related degenerative diseases, cancer, immune disorders, and infectious diseases; its core offerings include cryopreserved cell therapies utilizing mesenchymal-like adherent stromal cells (MLASCs), genetically modified and unmodified natural killer (NK) cells, CAR T-cells, and biomaterial products such as Biovance, Biovance 3L, and Interfyl for regenerative applications in wound care, oral healthcare, and ophthalmics. Founded in 2017 as a spin-out from Celgene Cell Therapeutics (with roots tracing to Anthrogenesis Corporation established in 1998), the company is headquartered in Florham Park, New Jersey, and operates a fully integrated GMP-capable manufacturing facility spanning 150,000 square feet for cell sourcing, expansion, cryopreservation, and biomaterial production from postpartum placentas obtained from healthy donors. Celularity serves healthcare providers, clinicians, and partners across the United States and select international markets, with business segments encompassing cell therapy, degenerative disease solutions, and bio-banking. In recent developments, Celularity entered a strategic partnership in October 2025 with DefEYE Inc., providing an in-kind investment in DefEYE's $12 million Series Seed Preferred Equity round, granting an exclusive sublicense for ophthalmic applications of its biomaterial products including Biovance, Biovance 3L, and Interfyl, and serving as exclusive contract manufacturer to expand into eye care amid DefEYE's reported 70% sales growth in 2024; the company also completed a major balance sheet restructuring to retire $41.6 million in senior secured debt, reported over sevenfold growth in net product sales through third quarter 2024 compared to the prior year, secured HCPCS Q Code approval for Biovance 3L from U.S. Centers for Medicare & Medicaid Services, and published Phase 2 trial results affirming the safety and efficacy of its placenta-derived cells (PDA-002) for diabetic foot ulcers complicated by peripheral artery disease.